GW583340 and GW2974, human EGFR and HER-2 inhibitors, reverse ABCG2- and ABCB1-mediated drug resistance.
about
BCRP/ABCG2 inhibition sensitizes hepatocellular carcinoma cells to sorafenibLamellarin O, a pyrrole alkaloid from an Australian marine sponge, Ianthella sp., reverses BCRP mediated drug resistance in cancer cells.Motesanib (AMG706), a potent multikinase inhibitor, antagonizes multidrug resistance by inhibiting the efflux activity of the ABCB1.In vitro, in vivo and ex vivo characterization of ibrutinib: a potent inhibitor of the efflux function of the transporter MRP1.A-770041 reverses paclitaxel and doxorubicin resistance in osteosarcoma cells.NVP-TAE684 reverses multidrug resistance (MDR) in human osteosarcoma by inhibiting P-glycoprotein (PGP1) function.Mechanisms of resistance to EGFR tyrosine kinase inhibitors.Telatinib reverses chemotherapeutic multidrug resistance mediated by ABCG2 efflux transporter in vitro and in vivoOsimertinib (AZD9291), a Mutant-Selective EGFR Inhibitor, Reverses ABCB1-Mediated Drug Resistance in Cancer Cells.Esters of the marine-derived triterpene sipholenol A reverse P-GP-mediated drug resistance.LRIG1 improves chemosensitivity through inhibition of BCL-2 and MnSOD in glioblastoma.ABCG2/BCRP: Specific and Nonspecific Modulators.Tivozanib reverses multidrug resistance mediated by ABCB1 (P-glycoprotein) and ABCG2 (BCRP).PD173074, a selective FGFR inhibitor, reverses ABCB1-mediated drug resistance in cancer cells.Implications of ABCG2 Expression on Irinotecan Treatment of Colorectal Cancer Patients: A Review.Quizartinib (AC220) reverses ABCG2-mediated multidrug resistance: In vitro and in vivo studies.Tyrphostin RG14620 selectively reverses ABCG2-mediated multidrug resistance in cancer cell lines.Tyrosine kinase inhibitors enhanced the efficacy of conventional chemotherapeutic agent in multidrug resistant cancer cells.Patients with CD133-negative colorectal liver metastasis have a poor prognosis after hepatectomy.Prognostic relevance of BRD7 expression in colorectal carcinoma.
P2860
Q28538126-1A234301-55C2-4F43-B033-05DB37A1BC20Q33963488-9A2854B4-87D1-4E5B-BDBE-29522B8A46C5Q34046157-7AA05A80-9245-4D4E-B80B-F66DC652805DQ34914312-BE800FE8-00EF-46FC-ADAA-58B9CF762C57Q35263202-2C2CF29F-1DA7-42DD-8C97-D6803EDBB746Q35851832-B8F9B7FD-4971-4A78-8B19-B43569F87A2EQ36238664-D29E22EA-B483-4C15-A873-0BC5B488C98CQ38710502-A8FDA083-3FAC-44D5-9777-B65CB45991C5Q38744729-4C9E6489-2D94-4FC3-A530-86C0095B0B54Q38887070-1AED6399-C6B9-4F14-A352-C8E9D34990CEQ38935017-63AC20B8-A9ED-4F6E-BDC0-708D68FA4B8BQ39049159-150C4A28-75C4-4761-BFA0-F938A3C75174Q39051270-759F5740-BC62-497C-8F0B-6CD12E383CC6Q39152151-26C7C9C6-471F-4E5F-A400-172A1F692464Q41660826-C1F7F750-57D2-4259-9DFF-01B88E0763F6Q47139045-D30A0D0C-A662-4670-9F67-78EB5B0F5919Q47821418-557CCFA0-AD14-4871-9A2F-60833C8E46D9Q49888021-9C7287F9-50C4-4989-AD70-3B9D0806C228Q50720110-1090E3F3-E9B9-4C74-B1E1-9E4415A1B6AAQ54280630-E022B4B9-4264-4BB1-8CF8-8A94A4127EB4
P2860
GW583340 and GW2974, human EGFR and HER-2 inhibitors, reverse ABCG2- and ABCB1-mediated drug resistance.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
GW583340 and GW2974, human EGF ...... BCB1-mediated drug resistance.
@en
GW583340 and GW2974, human EGF ...... BCB1-mediated drug resistance.
@nl
type
label
GW583340 and GW2974, human EGF ...... BCB1-mediated drug resistance.
@en
GW583340 and GW2974, human EGF ...... BCB1-mediated drug resistance.
@nl
prefLabel
GW583340 and GW2974, human EGF ...... BCB1-mediated drug resistance.
@en
GW583340 and GW2974, human EGF ...... BCB1-mediated drug resistance.
@nl
P2093
P2860
P50
P1476
GW583340 and GW2974, human EGF ...... ABCB1-mediated drug resistance
@en
P2093
Atish Patel
Jun-Jiang Chen
Kamlesh Sodani
Tanaji T Talele
Yue-Li Sun
Zhe-Sheng Chen
Zhi-Jie Xiao
P2860
P304
P356
10.1016/J.BCP.2012.02.028
P407
P577
2012-03-07T00:00:00Z